营收利润高速增长。2025年3月21日,翰森制药发布2024年年度业绩公告,2024年公司实现总收入122.61亿元,同比增长21.3%,实现归母净利润43.72亿元,同比增长33.4%创新驱动业绩增长成效显著。2024年公司创新药与合作产品收入约94.77亿元,同比增长38.1%,占总收入比例进一步上升至77.3%。分领域来看,肿瘤领域营收81.22亿元,占比66.2%;抗感染领域营收14.64...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.